Myasthenia Gravis Market Size, Share, Growth, And Industry Analysis, By Type (Drug Treatment and Rapid Immunotherapies), By Application (Hospitals, Clinics and Other), Regional Forecast By 2033

MYASTHENIA GRAVIS MARKET REPORT OVERVIEW

• 

   Request a Free Sample To Get More Information on this Market

The global myasthenia gravis market size was USD 13.48 billion in 2024 & the market is expected to reach USD 32.84 billion in 2033, exhibiting a CAGR of 10.4% during the forecast period.

The global COVID-19 pandemic has been unprecedented and staggering, with the myasthenia gravis market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.

The head, ocular, vertebral, and respiratory muscles are weakened in people with myasthenia gravis (MG), a continuous, persistent, and uncommon neuromuscular condition. Antibodies are made against the acetylcholine receptor (AchR), which normally prevents the normal flow of electrical impulses from nerves to limbs, in this autoimmune illness. Although symptoms of myasthenia can manifest at any age, women are more likely than men to get it, and it often manifests at its peak in men's 50s or 60s and women's 20s or 30s. Although there is no known treatment for gravis, individuals can control their symptoms with drugs and surgeries. In order to improve treatment and diagnosis of the autoimmune issues related to MG, research is being concentrated on a greater understanding of their characteristics.

The expansion of the global market for myasthenia gravis treatments is primarily driven by an increase in the number of clinical studies for treatment. Other factors boosting market expansion include ongoing research and development efforts, rising private sector investment, and the advancement of technologically sophisticated pharmaceuticals.

COVID-19 Impact

"Disruption in the Treatment of Patients with Gravis was Experienced due to the Pandemic"

The market for therapies for gravis was adversely affected by the COVID-19 epidemic. Immune system thinning medications known as immunosuppressives are frequently used. Infections such as COVID-19 can affect these persons as a result. On account of this, hospitals and clinics saw a dramatic drop in patient traffic during the outbreak in 2020. Supply chain difficulties and obstacles in the way of medication trials affected important firms. A disruption in the treatment of patients with myasthenia gravis also caused a loss in revenue that was anticipated by renowned firms for the novel drugs.

LATEST TRENDS

"Use of Soliris in the Treatment of Patients Suffering from Generalized MG"

The frequency of pipeline investigations for developing drugs in the myasthenia therapy sector is growing, which is projected to fuel market growth. For the treatment of adults with generalized myasthenia gravis who are anti-AchR antibody-positive, Soliris (eculizumab), manufactured by Alexion Pharmaceuticals, recently acquired authorization from both the U.S. FDA and the European Commission. The initial and only complement inhibitor licensed for this condition is Soliris. Monoclonal antibodies and immunosuppressants are being used more and more in an attempt to enhance long-term outcomes while reducing the amount of corticosteroid exposure that patients receive during their lifetime.

MYASTHENIA GRAVIS MARKET SEGMENTATION

By Type Analysis

According to type, the market can be segmented into Drug Treatment and Rapid Immunotherapies

By Application Analysis

Based on application, the market can be divided into Hospitals, Clinics and Other

DRIVING FACTORS

"Increase in Government Expenditure in the Healthcare Infrastructure Promotes the Gravis Market Expansion"

Demand for expensive treatments such as plasma exchange and intravenous immunoglobulin (IVIG) therapy is predicted to rise as a result of rising health care costs and per capita income around the world. Additionally, governments in emerging nations are making large expenditures in the upgrading of the healthcare system, which is probably going to expand access to healthcare. There will likely be a rise in demand for cutting-edge therapies, technologies, and treatments as a result. This will soon open up potential for IVIG and monoclonal antibody therapy in the myasthenia gravis sector.

"Expanding Need for Gravis Care in Hospitals will Shoot Up the Market Revenue Growth"

The myasthenia treatment market has been divided into three categories based on distribution channels: hospitals, clinics, and others. On account of more patient falls and the availability of cutting-edge healthcare infrastructure in industrialized nations, the hospital drugstore segment is anticipated to have the greatest revenue share during the projection period. A myasthenia emergency occurs in roughly 15-20% of individuals during their treatment cycle, needing hospitalization, due to the harmful effects of drugs reflecting the adverse effects. As a result, the aforementioned reasons are increasing the need for gravis care in hospitals, resulting in enhanced market revenue growth.

RESTRAINING FACTORS

"Costs Associated with MG Hinder the Market Expansion"

The expense of discovering and creating new treatments is significant, and it takes longer for them to become commercially viable. The never-approved IVIG and monoclonal antibody treatments are pricey therapy choices. When compared to the components and methods used to create conventional pharmaceutical goods, the expense of plasma gathering and production methods for IVIG medicines is considerable. Furthermore, due intravenous immunoglobulin (IVIG) products are made from a blood component, they call for extremely sophisticated methods of acquisition, filtration, and preservation. Compared to symptomatic medication therapy, which also requires hospitalization, plasmapheresis and thymectomy are more expensive. Cost is a key determinant in treatment decision-making, which is expected to restrain the worldwide myasthenia gravis market growth.

MYASTHENIA GRAVIS MARKET REGIONAL INSIGHTS

• 

   Request a Free Sample To Get Analysis on Major Geographic Market

"Rising Prevalence and Expanding Elderly Population in the Region Propel the Market Broadening "

The myasthenia gravis market share worldwide was dominated by North America in 2020. Two factors influencing the market's growth over the coming years are the condition's rising prevalence and the region's expanding elderly population. Furthermore, the region's strong healthcare infrastructure and advantageous reimbursement policies help to increase the rate of identification and treatment of the illness in both developing and emerging nations. These elements are expected to propel the market during the anticipated time frame.

The world's second-largest customer base belongs to Europe. This is a result of better funding and the establishment of numerous healthcare organizations for the detection and treatment of uncommon illnesses including myasthenia gravis. In order to find effective treatments and improve diagnostics for rare conditions in related EU member states, the European Joint Programme on Rare Diseases was established, in accordance with a 2019 article in a national media in Europe.

KEY INDUSTRY PLAYERS

"Key Players Focus on Developing Cutting-edge Therapies to Gain the Upper Hand in the Market"

The introduction of cutting-edge drug therapies and astute acquisitions of other local manufacturers are ongoing efforts by big firms to expand their product portfolios. Important players are also focusing on using their current drugs for myasthenia treatment more frequently. This syndrome is being explored as a potential target for the immunosuppressant drug Prograf, which was created by Astellas Pharmaceuticals to reduce organ and tissue resistance. Tirasemtiv, a drug developed by Cytokinetics for muscle spasms, is also being tested for this problem.

List of Top Myasthenia Gravis Companies

• F Hoffmann-La Roche (Switzerland)
• CSL Behring (U.S.)
• Grifols (Spain)
• Alexion Pharmaceutical (U.S.)
• Avadel Pharmaceuticals (Ireland)
• Baxter International (U.S.)
• Novartis (Switzerland)
• Bausch Health (Canada)
• Takeda Pharmaceutical Company (Japan)

REPORT COVERAGE

This report covers the myasthenia gravis market. The CAGR expected to be in during the forecast period, and also the USD value in 202 and what it is expected to be in 2028. The effect COVID-19 had on the market in the beginning of the pandemic. The latest trends taking place in this industry. The factors that are driving this market as well as the factors that are restraining the growth of industry. The segmentation of this market based on type and applications. The region leading in the industry and why they will continue to do so during the forecast period. Further, the key market players, what all is being done by them to stay ahead of their competition as well as retain their market positions. All these details are covered in the report.